Adjuvant immunotherapy in muscle-invasive urothelial carcinoma – Author's reply

Cross-trial comparisons of clinical data should always be investigated with care because of inherent study heterogeneity and assumptions made to make studies commensurable. These considerations pose challenges when putting the findings from IMvigor010—our phase 3 adjuvant study 1 Bellmunt J Hussain M Gschwend JE et al. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label,...